Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025Pharmacogenomics

Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

ETEmytis TavakoliLMLeen MagarbehSESamar S. M. Elsheikh

Discussion

Loading...

Member takes

Overview

Systematic review reveals pharmacogenetic testing improves treatment response in depression, suggesting its value in personalized medicine.

Key Points

  • Pharmacogenetic testing improves antidepressant response rates in patients with depression.
  • Studies showed higher remission rates at 8 and 12 weeks compared to treatment-as-usual (TAU).
  • Randomized controlled trials and meta-analyses assessed the effectiveness of CYP2D6 and CYP2C19 testing.
  • Findings indicate that pharmacogenetic testing is crucial for achieving earlier remission in depression.

Cite This Study

Tavakoli et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d0908https://doi.org/10.1080/14622416.2025.2541402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Toward precision psychiatry: integrating pharmacogenomics and multimodal clinical data for personalized antidepressant response prediction2026
  2. 2Utilizing Pharmacogenomics Results to Guide Antidepressant Selection: A Case Report2024
  3. 3Exploring the Efficacy of Pharmacogenomic Testing in Personalizing Antidepressant Therapy2024
  4. 4Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis2024 · 24 citations
  5. 5Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use2026